ReviewCureus2025
Utility of Artificial Intelligence in Antibiotic Development: Accelerating Discovery in the Age of Resistance.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Precision antimicrobials: the next paradigm shift after broad-spectrum therapy.Frontiers in microbiology · 2026Article
- A comprehensive review of AI innovations for tackling antimicrobial resistance.Le infezioni in medicina · 2026Review
- Leveraging artificial intelligence for One Health: opportunities and challenges in tackling antimicrobial resistance - scoping review.One health outlook · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is a growing public health issue, complicating the treatment of bacterial infections and increasing morbidity and mortality globally. This phenomenon, which occurs as a result of the ability of bacteria to adapt and evade conventional treatments, requires innovative strategies to address it. Artificial intelligence (AI) emerges as a transformative tool in this context, helping accelerate the identification of molecules with antimicrobial potential and optimize the design of new drugs. This article analyzes the usefulness of AI in antibiotic development, highlighting its benefits in terms of time, cost, and efficiency in the fight against resistant bacteria, as well as the challenges associated with its implementation in the biomedical field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.